Sugi Predict

Sugi Predict / Targets / CCR9

CCR9

C-C chemokine receptor type 9 · P51686 · CCR9 on Sugi Atlas →

9,956 patent compounds predicted against CCR9, 4,724 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL343350 SCHEMBL343350 1.00 20/20
SCHEMBL343855 SCHEMBL343855 1.00 20/20
SCHEMBL344344 SCHEMBL344344 1.00 20/20
SCHEMBL343333 SCHEMBL343333 0.82 20/20
SCHEMBL344136 SCHEMBL344136 0.79 20/20
SCHEMBL344369 SCHEMBL344369 0.79 20/20
SCHEMBL343042 SCHEMBL343042 0.78 20/20
SCHEMBL344940 SCHEMBL344940 0.78 20/20
SCHEMBL343923 SCHEMBL343923 0.76 20/20
SCHEMBL342886 SCHEMBL342886 0.75 20/20
SCHEMBL343741 SCHEMBL343741 0.73 20/20
SCHEMBL344687 SCHEMBL344687 0.73 20/20
SCHEMBL344490 SCHEMBL344490 0.72 20/20
SCHEMBL343310 SCHEMBL343310 0.70 20/20
SCHEMBL343838 SCHEMBL343838 0.70 20/20
SCHEMBL343479 SCHEMBL343479 0.68 20/20
SCHEMBL344969 SCHEMBL344969 0.68 20/20
SCHEMBL1094107 SCHEMBL1094107 0.67 20/20
SCHEMBL344291 SCHEMBL344291 0.66 20/20
SCHEMBL1094865 SCHEMBL1094865 0.66 20/20

Clinical trials — most relevant to CCR9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation PHASE3SUSPENDED
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia PHASE3SUSPENDED
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver PHASE2COMPLETED
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
U69-CART-Cells For R/R T-ALL PHASE1RECRUITING
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients PHASE1COMPLETED
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) PHASE1RECRUITING
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation PHASE1COMPLETED
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer PHASE1COMPLETED
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation PHASE1RECRUITING
Significance of MAIT Cells in Inflammatory Bowel Disease nanUNKNOWN
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis nanNOT_YET_RECRUITING
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA nanRECRUITING
Measuring the Healthy Pediatric Inflammatory Response to Vaccination. nanENROLLING_BY_INVITATION
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy nanCOMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response nanACTIVE_NOT_RECRUITING
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure nanUNKNOWN
IL-11 in the Development of Multiple Sclerosis nanUNKNOWN
Lung-Resident Memory Th2 Cells in Asthma nanACTIVE_NOT_RECRUITING
Comparative Study Between Alzheimer's and Multi-infarct Dementia nanUNKNOWN
Tregs CD25 CXCL9 in Vitiligo nanUNKNOWN
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
Value of Various Chemokines in the Detection and Follow up of RCC nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCR9 binder may also engage these)

ProteinNameSimilarity
Q9WUT7 — 1.000 Q9WUT7 →
Q1WLP9 — 0.997 Q1WLP9 →
CCR7 C-C chemokine receptor type 7 0.984 landscape →
Q5MD62 — 0.983 Q5MD62 →
CCR8 C-C chemokine receptor type 8 0.983 landscape →
P51680 — 0.982 P51680 →
P47774 — 0.982 P47774 →
CCR4 C-C chemokine receptor type 4 0.981 landscape →
P56484 — 0.978 P56484 →
Q8MJW8 — 0.977 Q8MJW8 →
Q95ND1 — 0.977 Q95ND1 →
P61815 — 0.977 P61815 →
Q28003 — 0.976 Q28003 →
O97665 — 0.975 O97665 →
Q95NE8 — 0.975 Q95NE8 →
P56439 — 0.975 P56439 →
Q4VA82 — 0.974 Q4VA82 →
P61755 — 0.974 P61755 →
Q9TV48 — 0.974 Q9TV48 →
P56493 — 0.974 P56493 →
Q9EQ16 — 0.974 Q9EQ16 →
Q95NC6 — 0.974 Q95NC6 →
P51682 — 0.974 P51682 →
O97878 — 0.974 O97878 →
CXCR2 C-X-C chemokine receptor type 2 0.973 landscape →
Q95NC8 — 0.973 Q95NC8 →
P79960 — 0.973 P79960 →
P61814 — 0.973 P61814 →
P61813 — 0.973 P61813 →
Q95NC0 — 0.973 Q95NC0 →